OBJECTIVE: To assess multiple sclerosis (MS) associated fatigue after the first 6 months of natalizumab treatment. METHODS: Prospective, open-label, uncontrolled study. Fatigue was measured before treatment initiation and at month 6 with the Modified Fatigue Impact Scale (MFIS) and the Fatigue Severity Scale (FSS) in 42 patients. Subjective impression of well-being was assessed with a visual analogue scale (1-10). RESULTS:42 patients were followed (mean age 35.1 years, 60% female, mean EDSS 3.7). The mean total MFIS were 45.8 (17.5) at baseline and decreased to 40.1 (18.0) (p<0.01) at month 6. Mean scores on the VAS for subjective impression of well-being increased from 5.5 (1.9) to 6.1 (2.1) at month 6 (p<0.01). Pre-treatment annual relapse rate decreased from 2.2 to 0.2, gadolinium enhancing lesions were reduced by 96% with natalizumab. There was no correlation of gadolineum enhancing lesions and fatigue scores. CONCLUSION:Fatigue and well-being improved after treatment initiation with natalizumab. A randomized controlled trial is necessary to come to definite conclusions as to a potential effect of natalizumab on fatigue in MS.
RCT Entities:
OBJECTIVE: To assess multiple sclerosis (MS) associated fatigue after the first 6 months of natalizumab treatment. METHODS: Prospective, open-label, uncontrolled study. Fatigue was measured before treatment initiation and at month 6 with the Modified Fatigue Impact Scale (MFIS) and the Fatigue Severity Scale (FSS) in 42 patients. Subjective impression of well-being was assessed with a visual analogue scale (1-10). RESULTS: 42 patients were followed (mean age 35.1 years, 60% female, mean EDSS 3.7). The mean total MFIS were 45.8 (17.5) at baseline and decreased to 40.1 (18.0) (p<0.01) at month 6. Mean scores on the VAS for subjective impression of well-being increased from 5.5 (1.9) to 6.1 (2.1) at month 6 (p<0.01). Pre-treatment annual relapse rate decreased from 2.2 to 0.2, gadolinium enhancing lesions were reduced by 96% with natalizumab. There was no correlation of gadolineum enhancing lesions and fatigue scores. CONCLUSION:Fatigue and well-being improved after treatment initiation with natalizumab. A randomized controlled trial is necessary to come to definite conclusions as to a potential effect of natalizumab on fatigue in MS.
Authors: Charlotte D'Mello; Kiarash Riazi; Tai Le; Katarzyna M Stevens; Arthur Wang; Derek M McKay; Quentin J Pittman; Mark G Swain Journal: J Neurosci Date: 2013-09-11 Impact factor: 6.167
Authors: John N Ratchford; Regina Brock-Simmons; Amanda Augsburger; Sonya U Steele; Kristie Mohn; Mandi Rhone; Jinyan Bo; Kathleen Costello Journal: Int J MS Care Date: 2014
Authors: Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds Journal: Int J MS Care Date: 2013
Authors: Judith J Stephenson; David M Kern; Sonalee S Agarwal; Ruth Zeidman; Krithika Rajagopalan; Siddhesh A Kamat; John Foley Journal: Health Qual Life Outcomes Date: 2012-12-27 Impact factor: 3.186
Authors: Anders Svenningsson; Eva Falk; Elisabeth G Celius; Siegrid Fuchs; Karen Schreiber; Sara Berkö; Jennifer Sun; Iris-Katharina Penner Journal: PLoS One Date: 2013-03-21 Impact factor: 3.240